Patents Assigned to Merck Sharp and Dohme Corp.
  • Addition of nucleases directly to cell culture to facilitate digestion and clearance of host cell nucleic acids
    Patent number: 11268071
    Abstract: The present invention provides an efficient process for culturing viruses in the presence of an endonuclease and for producing vaccines, typically from live attenuated viruses, under conditions to reduce the presence of host cell DNA and eliminate the need for a post-harvest DNA digestion step.
    Type: Grant
    Filed: March 28, 2018
    Date of Patent: March 8, 2022
    Assignee: Merck Sharp and Dohme Corp.
    Inventors: Yi Li, Matthew Woodling, Adam Kristopeit
  • Triazole derivatives as inhibitors of 11-? hydroxysteroid dehydrogenase-1
    Patent number: 8026264
    Abstract: Triazole derivatives of structural formula I are selective inhibitors of the 11?-hydroxysteroid dehydrogenase-1. The compounds are useful for the treatment of diabetes, such as noninsulin-dependent diabetes (NIDDM), hyperglycemia, obesity, insulin resistance, dyslipidemia, hyperlipidemia, hypertension, Metabolic Syndrome, and other symptoms associated with NIDDM.
    Type: Grant
    Filed: May 26, 2004
    Date of Patent: September 27, 2011
    Assignee: Merck Sharp and Dohme Corp.
    Inventors: Sherman T. Waddell, Gina M. Santorelli, Milana M. Maletic, Aaron H. Leeman, Xin Gu, Donald W. Graham, James M. Balkovec, Susan D. Aster